McKinsey hit with a $650M fine for deceiving US about opioid consulting work

Max Bayer

Pharma Reporter

McKinsey has accepted a $650 million fine after admitting that it helped accelerate sales of Purdue Pharma’s opioid products and misled the US government about …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

McKinsey hit with a $650M fine for deceiving US about opioid consulting work

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

EMA's committee says expanded label for Lilly's Mounjaro into sleep apnea not necessary

Xaira hires former Roche exec as CMO; 'Tis the season for retirements at Alnylam, Regeneron

CDK4 inhibitors from BeiGene and Pfizer, ALX’s CD47 drug take the stage at SABCS

AbbVie makes another small I&I acquisition, buying Nimble for $200M

The key to faster, more impactful research? Put patients in the driver’s seat

McK­in­sey hit with a $650M fine for de­ceiv­ing US about opi­oid con­sult­ing work

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses

EMA's com­mit­tee says ex­pand­ed la­bel for Lil­ly's Moun­jaro in­to sleep ap­nea not nec­es­sary

Xaira hires for­mer Roche ex­ec as CMO; 'Tis the sea­son for re­tire­ments at Al­ny­lam, Re­gen­eron

CDK4 in­hibitors from BeiGene and Pfiz­er, ALX’s CD47 drug take the stage at SABCS

Ab­b­Vie makes an­oth­er small I&I ac­qui­si­tion, buy­ing Nim­ble for $200M

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

McKinsey hit with a $650M fine for deceiving US about opioid consulting work

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

EMA's committee says expanded label for Lilly's Mounjaro into sleep apnea not necessary

Xaira hires former Roche exec as CMO; 'Tis the season for retirements at Alnylam, Regeneron

CDK4 inhibitors from BeiGene and Pfizer, ALX’s CD47 drug take the stage at SABCS

AbbVie makes another small I&I acquisition, buying Nimble for $200M

The key to faster, more impactful research? Put patients in the driver’s seat